Companies › Neurotech Pharmaceuticals
2 active drug programs in 2 registered trials: 1 Phase 3, 1 Phase 4; Ophthalmology; next expected readout May 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NT-501/revakinagene taroretcel-lwey Surgically implanted intraocular device expressing recombinant human ciliary neurotrophic | CTGF | Phase 4 | Macular Telangiectasia Type 2 (MacTel) | Jan 2032 |
| NT-501 Cell-based therapy implant manufactured using hollow fiber membrane | – | Phase 3 | Macular Telangiectasia Type 2 | May 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06397131 | NT-501 | Phase 3 | Macular Telangiectasia Type 2 | Ophthalmology | May 2028 |
| NCT06971939 | NT-501/revakinagene taroretcel-lwey | Phase 4 | Macular Telangiectasia Type 2 (MacTel) | Ophthalmology | Jan 2032 |
–
Innostellar Biotherapeutics MeiraGTx Ocular UK Tecnoquimicas Price Vision Group NexThera
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.